Cytokinetics (CYTK) EVP Callos exercises options and sells 11,333 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction involving company common stock. He exercised 11,333 shares through a non-qualified stock option with a $39.13 per share exercise price, originally exercisable from April 6, 2023 and expiring on March 6, 2033. The same day, he executed an open-market sale of 11,333 common shares at $77.25 per share. Following these transactions, he held 58,555 common shares directly, and the option position showed 13,070 option shares remaining in that grant.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 11,333 shares ($875,474)
Net Sell
3 txns
Insider
Callos Andrew
Role
EVP, Chief Commercial Officer
Sold
11,333 shs ($875K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (Right to Buy) | 11,333 | $0.00 | -- |
| Exercise | Common Stock | 11,333 | $39.13 | $443K |
| Sale | Common Stock | 11,333 | $77.25 | $875K |
Holdings After Transaction:
Non-Qualified Stock Option (Right to Buy) — 13,070 shares (Direct, null);
Common Stock — 69,888 shares (Direct, null)
Footnotes (1)
Key Figures
Shares sold: 11,333 shares
Sale price: $77.25 per share
Options exercised: 11,333 shares
+5 more
8 metrics
Shares sold
11,333 shares
Open-market sale of common stock
Sale price
$77.25 per share
Price for 11,333 common shares sold
Options exercised
11,333 shares
Non-Qualified Stock Option exercise
Option exercise price
$39.13 per share
Strike price of Non-Qualified Stock Option
Shares held after
58,555 shares
Common stock directly owned post-transaction
Options remaining in grant
13,070 shares
Non-Qualified Stock Option balance after exercise
Option exercisable date
April 6, 2023
Non-Qualified Stock Option became exercisable
Option expiration date
March 6, 2033
Non-Qualified Stock Option expiry
Key Terms
Non-Qualified Stock Option, open-market sale, derivative security, exercise price, +1 more
5 terms
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option (Right to Buy)""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price: "39.1300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
direct ownership financial
"ownership_type: "direct" and ownership_code: "D""
FAQ
What insider transaction did CYTOKINETICS INC (CYTK) report for Andrew Callos?
CYTOKINETICS INC reported that EVP and Chief Commercial Officer Andrew Callos exercised 11,333 stock options and sold 11,333 common shares. The activity was reported on a Form 4 insider trading filing detailing the exercise-and-sell pattern.
What stock options did Andrew Callos exercise in this CYTOKINETICS Form 4?
He exercised 11,333 shares from a Non-Qualified Stock Option with a $39.13 exercise price. The option became exercisable on April 6, 2023 and carries an expiration date of March 6, 2033, as shown in the filing.
Was the CYTOKINETICS (CYTK) transaction by Andrew Callos a net sale or purchase?
The filing reflects a net sale, with 11,333 shares sold after exercising 11,333 options. The transactionSummary in the Form 4 shows a net-sell direction based on the reported share movements.